Sucralfate pp 35-45 | Cite as

History of the Development of Sucralfate

  • Akira Ishimori


Sucralfate was introduced in Japan as a selective ulcer-protecting agent in 1968 and it is currently accepted worldwide as a nonsystemic site protector. This agent has an unusual developmental history among the drugs for peptic ulcer disease (PUD). The development of sucralfate is a true reflection of international collaboration.


Duodenal Ulcer Gastric Ulcer Ulcer Healing Nosocomial Pneumonia Gastric Mucus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Babkin BP Komarov SA: The influence of gastric mucus on peptic digestion. Can Med Assoc J 27:463–469, 1932. The pepsin-suppressing activity of chondroitin sulfate in mucus is described.PubMedGoogle Scholar
  2. 2.
    Cook DL, Eich S, Cammarata PS: Comparative pharmacology and chemistry of synthetic sulfated polysaccharide. Arch Int Pharmacodyn 144:1–19, 1963. This paper gives a detailed description of synthetic antipeptic agents.PubMedGoogle Scholar
  3. 3.
    Cayer D, Raffin JM: Effect of Depepsin in the treatment of peptic ulcer. Ann NY Acad Sci 140:744–746, 1967. The first evaluation of amylopectin sulfate, developed in the United States, in PUD patients.PubMedCrossRefGoogle Scholar
  4. 4.
    Watt J, Marcus R: Ulceration of the colon in rabbits fed sulfated amylopectin. J Pharm Pharmacol 24:68–69, 1972. A major side effect of antipeptic agents is intestinal, especially colonic ulceration.PubMedCrossRefGoogle Scholar
  5. 5.
    Ishimori A: Mechanism of the antipeptic action of anionic carbohydrate and its clinical application for the treatment of peptic ulcer. Tohoku J Exp Med 103:141–157, 1971. The suppression of peptic activity in gastric juice by sucralfate is transient.PubMedCrossRefGoogle Scholar
  6. 6.
    Yamagata S, Ishimori A, et al: Clinical evaluation of pharmacotherapy for peptic ulcer with antipepsin agents by double blind technique. Tohoku J Exp Med 110:377–404, 1973. Gastric ulcer healing is improved after sucralfate therapy.PubMedCrossRefGoogle Scholar
  7. 7.
    Marks IN: A skeptical view of medical treatment, in Truelove SC, Willoughby CP (eds): Topics in Gastroenterology. Oxford, Blackwell, vol 7, pp 111–129, 1979. Sucralfate has comparable efficacy to cimetidine in healing gastroduodenal ulcers.Google Scholar
  8. 8.
    Marks IN, Weight JP, Lucks W, et al. Relapse rates after initial ulcer healing with sucralfate and cimetidine. Scand J Gastroenterol 17:429–432, 1982. Relapse rates after sucralfate-induced healing are lower compared with cimetidine-induced healing.PubMedCrossRefGoogle Scholar
  9. 9.
    Moshal MG, Spitaels J-M, Manion GL: Double-blind placebo-controlled evaluation of one year therapy with sucralfate on healed duodenal ulcer. Scand J Gastroenterol 18(suppl 83):57–59, 1983. Sucralfate is superior to placebo in keeping DU in remission.Google Scholar
  10. 10.
    Bigley LD, Giesing D: Studies on acting mechanism of sucralfate, in Caspary WF (ed): Duodenal Ulcer, Gastric Ulcer: Sucralfate. Munich, Urban &0026; Schwarzenberg, 1981, pp 3–12.Google Scholar
  11. 11.
    Harrington SJ, Schlegel JF, Code CF: The protective effect of sucralfate on the gastric mucosa in rats. J Clin Gastroenterol 3(suppl 2):129–134, 1981.PubMedGoogle Scholar
  12. 12.
    Steiner K, Garbe A: Specific binding of 14C-sucralfate to acetic acid-induced gastric and duodenal ulcers of the rat, in Caspary WF (ed): Duodenal Ulcer, Gastric Ulcer: Sucralfate. Munich, Urban &0026; Schwarzenberg, 1981, pp 19–21.Google Scholar
  13. 13.
    Sasaki H, Hinohara Y, Tsunoda Y, et al: Binding sucralfate to duodenal ulcer in man. Scan J Gastroenterol 18(suppl 83):13–14, 1983.Google Scholar
  14. 14.
    Quinton A: Binding duration of sucralfate assessed at different doses. International update: GL therapy, Maui, 1987. References 10–14 discuss binding of sucralfate to the base of peptic ulcers.Google Scholar
  15. 15.
    Nagashima R, Hirano T: Selective binding of sucralfate to ulcer lesion. Arzneim Forsch 30:80–83, 1980. This study illustrates the selective binding of sucralfate to an ulcer base.Google Scholar
  16. 16.
    Nakazawa S, Nagashima R, Samloff IM: Selective binding of sucralfate to gastric ulcer in man. Dig Dis Sci N S 26:297–300, 1981. This is a fundamental study indicating selective binding of sucralfate to gastric ulcers in man.CrossRefGoogle Scholar
  17. 17.
    Driks MR, Craven DE, Celli BR, et al: Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine-type 2 blockers. N Engl J Med 317:1376–1382. 1987. Nosocomial pneumonia was thought to occur more often after H2RA therapy of intubated patients.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press 1995

Authors and Affiliations

  • Akira Ishimori
    • 1
  1. 1.Department of Clinical and Laboratory MedicineTohoku University School of MedicineSondaiJapan

Personalised recommendations